Vitiligo improvement in a patient with ankylosing spondylitis treated with infliximab.
Ankylosing spondylitis (AS) is a disabling disease affecting the enthesis and joints of the spine and peripheral sites. Tumour necrosis factor alpha (TNF-alpha) is a proinflammatory mediator which plays a significant role in the pathogenesis of AS. Infliximab (a chimeric monoclonal antibody which blocks the activity of TNF-alpha) is one of the most effective therapies of AS thus far. Vitiligo is a depigmenting disorder of the skin of unknown aetiology affecting 0.5-1% of the population. Here we describe the effect of infliximab on vitiligo in a patient with AS.
Simón
J-Abraham
JA
Medical Research Centre, UMAE-Yucatán, IMSS, Department of Internal Medicine, CEM Hospital, Faculty of Medicine, Universidad Nacional Autónoma de México, México, Mexico.
Burgos-Vargas
Rubén
R
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000069285:Infliximab; D008297:Male; D013167:Spondylitis, Ankylosing / Q000150:complications / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014820:Vitiligo / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology
D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab